Study on DRAP1: Potential Drug Target and Biomarker (G10589)

Target Name: DRAP1

NCBI ID: G10589

DRAP1

Study on DRAP1: Potential Drug Target and Biomarker

DRAP1 (Negative cofactor 2-alpha), a protein that is expressed in various tissues throughout the body, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function have made it an attractive target for researchers to study, and recent studies have shed light on its potential role in these conditions.

DRAP1, also known as negative cofactor 2-alpha (NCF2?±), is a protein that is expressed in various tissues, including the brain, muscle, heart, liver, and pancreas. It is a key regulator of cell signaling pathways, and its abnormalities The expression has been linked to the development and progression of various diseases.

One of the most promising aspects of DRAP1 is its potential as a drug target. The use of small molecules, such as drugs that bind to specific regions of the protein, has been shown to be an effective way to target DRAP1 and inhibit its activity. This approach has been used to develop new treatments for a variety of conditions, including neurodegenerative diseases, cancer, and autoimmune disorders.

For example, researchers have used small molecules to inhibit the activity of DRAP1 and prevent its regulation of microtubules, a structure that is critical for cell signaling. This has led to the development of new treatments for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

In addition to its potential as a drug target, DRAP1 has also been identified as a potential biomarker for several diseases. Its expression has been shown to be elevated in a variety of tissues and conditions, including cancer, neurodegenerative diseases, and autoimmune disorders. This makes it an attractive candidate for use as a diagnostic marker or target for therapeutic intervention.

One of the key challenges in studying DRAP1 is its complex structure and function. The protein is composed of multiple domains, including an N-terminus that is involved in its stability and a C-terminus that is involved in its interactions with other proteins. The middle region of the protein contains a variety of conserved motifs that are involved in its regulation of cell signaling pathways.

In addition to its structure, DRAP1's function is also of interest. Its involvement in cell signaling pathways has led to its implication in a variety of diseases. For example, its regulation of microtubules has been linked to the development of neurodegenerative diseases, and its inhibition has been shown to be effective in treating these conditions.

In conclusion, DRAP1 is a protein that has great potential as a drug target and biomarker for a variety of diseases. Its unique structure and function have made it an attractive target for researchers to study, and recent studies have shed light on its potential role in these conditions. Further research is needed to fully understand its mechanisms of action and its potential as a therapeutic intervention.

Protein Name: DR1 Associated Protein 1

Functions: The association of the DR1/DRAP1 heterodimer with TBP results in a functional repression of both activated and basal transcription of class II genes. This interaction precludes the formation of a transcription-competent complex by inhibiting the association of TFIIA and/or TFIIB with TBP. Can bind to DNA on its own

The "DRAP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DRAP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets